Background: Identifying metabolomic profiles of children with asthma has the
| INTRODUCTION
Asthma is the most common chronic illness in U.S. children, and results in substantial morbidity as well as health care costs, with over $50 billion dollars spent annually. 1 Asthma exacerbations are the most common health-related cause of lost school days, 1 rendering asthma a considerable public health burden. Asthma is a heritable disease with both environmental and genetic components. Investigators have successfully identified metabolite biomarkers for Type 2 Diabetes, Alzheimer's disease and cardiovascular disease, [5] [6] [7] [8] leading to the discovery of novel disease pathways for these conditions. Existing asthma metabolomic studies [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] have reported promising findings, identifying biologically plausible metabolites related to tricarboxylic acid (TCA) metabolism, hypermethylation, phospholipid regulation, hypoxic and oxidative stress, immune reaction and inflammation that have been associated with asthma and asthma severity. Nevertheless, the studies to date are limited by diagnostic heterogeneity, sample size, and number of metabolites, and most findings are yet to be replicated in independent populations. As such, the use of metabolomics in asthma studies remains in the early stages with much knowledge to be gained.
The goal of this study is to identify differences in metabolomic profiles for children with and without a current diagnosis of asthma, using an untargeted metabolomic profiling approach. We sought to determine whether children with current asthma have altered metabolic profiles as compared to controls without current asthma. Our goals were to (i) determine the ability of a broad spectrum metabolic profile to discriminate between current asthma cases vs. controls (ii) identify specific individual metabolites associated with current asthma and (iii) validate these findings using an independent population. 23 The Institutional Review
| METHODS AND MATERIALS
Board of Harvard Pilgrim Health Care approved the study protocols.
All mothers participating in the study provided written informed consent and the children provided verbal assent. A total of 1,116
mother-child pairs (with children aged 6-10 years) attended an inperson mid-childhood study visit and 648 assenting children provided fasting blood samples. Metabolomic assays were originally performed for a study of childhood obesity and metabolomics in Project Viva. 24 Given funding limitations, we selected 300 children for analysis, deliberately oversampling for maternal and child for obesity. Subjects were oversampled for obesity as the original analysis was focused on studying obesity. 24 After further exclusion of 38 children with inadequate plasma volume for the metabolomic assays, 262 children (84 obese, 28 overweight and 150 normal weight participants) had metabolomic data. Of 262, we excluded from this analysis 21 children with past asthma diagnosis, and four with inadequate information on current asthma. Thus, the final analytic sample included 237.
We assessed current asthma during the mid-childhood visit (mean age 8.0 years). We defined current asthma in mid-childhood as maternal report of ever diagnosed with asthma by a healthcare professional (assessed on the mid-childhood questionnaire) plus for Project Viva (see Appendix S1 for details). We used physician's diagnosis of asthma to define cases in VDAART at age three followup. 28 Parental report of physician's diagnosis of asthma was taken directly from the offspring questionnaires.
| Replication population

| Statistical analysis
Analyses were conducted in R. 29 Differences in maternal and child demographic characteristics between cases and controls were assessed using t-tests for continuous variables and chi-square tests for categorical variables.
| Partial least squares discriminant analysis
Metabolite features were analysed as measured LC-MS peak areas, which are proportional to feature concentration and can be compared for any given metabolite (relative quantitation). Partial least squares discriminant analysis (PLS-DA) was conducted using MetaboAnalyst v.2.5 (http://www.metaboanalyst.ca/) 30 to determine the combined ability of the 345 identified metabolites to discriminate asthma cases from controls. PLS-DA identifies latent factors, or components, that best describe the relationships between the metabolites, while best predicting asthma status. A sevenfold internal cross-validation procedure was implemented to guard against model over-fitting, and the overall significance of the model's discriminatory ability was evaluated using permutation testing; specifying 'prediction accuracy during training' and 2000 permutations.
| Individual metabolite analysis
We also conducted logistic regression on individual metabolites, to determine their relationship to asthma case status. Models were adjusted for maternal age, maternal education, smoking during pregnancy, child's gender, age, BMI z-score and race/ethnicity. Associations were expressed as odds ratios (95%CI) for current asthma per unit increase in metabolite.
| Replication of significant findings
For replication, metabolites significantly associated with asthma in Project Viva were tested in an independent cohort of children from the VDAART clinical trial. We performed logistic regression analysis to determine if these metabolites were associated with asthma diagnosis at age 3 years. Analyses were adjusted for child's age, gender, BMI, race/ethnicity, maternal education level and maternal age. We report one-sided P values for the replication analysis.
| RESULTS
| Discovery population
Characteristics of the discovery population are presented in Table 1 .
Of the 237 children in Project Viva, 52.3% were female and 19.4%
had a mother-reported a diagnosis of current asthma. The mean KELLY ET AL.
| 1299 (AESD) age was 8.0 (AE0.9) years. The majority of children with current asthma were also sensitized to allergens. Seventy-two percent had a positive specific IgE test (≥0.35 IU/mL) to at least one of the specific indoor, outdoor or food allergens tested. In contrast, 49% of control subjects were sensitized to allergens. There were also notable differences between children with vs. without current asthma with respect to maternal age (30.3 vs 32.5 years, P = .02) and education (37.8% vs 63.9% college graduates, P = .002) and child age (8.4 vs 7.9 years, P = .02), race/ethnicity (26.1% vs 64.4% white, P ≤ .0001) and BMI z-scores (1.45 vs 0.66, P < .0001). There were no differences between children with vs without current asthma with respect to child's gender or maternal pregnancy smoking status.
We also collected information on asthma medication use and asthma severity in children with current asthma. The vast majority (80%) of current asthmatics were taking inhaled corticosteroids. In general, most current asthmatics in Project Viva showed mild to moderate disease severity. None of the current asthmatics were hospitalized in the past year for asthma. Most children with current asthma did not require emergency treatment for asthma symptoms in the past year (72%), although 17% reported one emergency room visit for asthma, 9% reported visiting the emergency room 2-3 times in the past year, with 2% reporting 3 or more visits. A little over half of the children (58%) with current asthma occasionally missed school because of asthma symptoms; 20% report one missed school day, 26% report 2-3 missed school days, and 11% report more than three missed school days over a 1 year time period.
In VDAART, cases of current asthma were generally mild. Only 38% of children received any medication for wheezing, wheezy bronchitis or asthma since their last follow-up. Seventeen percent of current asthmatics report seeing a doctor because of wheezing, asthma, wheezing or asthmatic bronchitis since their last follow-up.
| Replication population
Of the 411 children with available metabolomics data in the VDAART population, 219 (53%) were male and 108 (26%) developed asthma by age three. VDAART participants were of diverse race/ethnic backgrounds, and were 48% African American, 33% white and 19% other race. Of the children with current asthma in VDAART, 58% were sensitized to at least one of the indoor, outdoor or food allergens tested, while approximately half (48%) of the control subjects were sensitized to allergens.
| Partial least squares discriminant analysis
There was no evidence in these analyses that a specific profile signature derived from the 345 identified metabolites differed between asthma cases and controls in Project Viva ( Figure S1 ). After sevenfold internal cross-validation accuracy was 0.8, but the R 2 and Q 2 were only 0.25 and 0.05, respectively, for the first component, indicating that the model was not robust. This was confirmed by the permutation testing (permuted P = .134).
T Allergen sensitization numbers reflect some missing data; 215 subjects out of 237 had allergen sensitization testing.
| Individual metabolite analysis
Of all of the metabolites tested in Project Viva for associations with current asthma case status, none were statistically significant after adjustment for multiple comparisons. However, 10 metabolites were nominally significant at the P < .05 level (Table 2) . A one unit increase in N1-Methyl-2-pyridone-5-carboxamide, a metabolite in the nicotinamide pathway, was associated with an increased odd of asthma (OR = 2.79, 95% CI 1.10-7.97). The relationship between N1-Methyl-2-pyridone-5-carboxamide and asthma case status was replicated (Table 3) in the VDAART cohort (OR = 1.27, P = .04 (onesided P value)). The pyrimidine metabolite 5,6-dihydrothymine was associated with reduced odds of asthma (OR = 0.44, 95% CI 0.21-0.86) in Project Viva (Table 2 ), but showed the opposite direction of effect in VDAART (Table 3 Based on prior reports, we looked to see if plasma cortisone was lower in current asthmatics on ICS as compared to untreated current asthmatics in Project Viva. We did not see an association between ICS use and lower cortisone levels in current asthma cases (P > .9
for t-test comparisons). However, the very high ICS treatment rates in current asthmatics (80%) meant that a comparison with untreated current asthmatics was likely underpowered.
| DISCUSSION
We identified metabolites associated with asthma by profiling the plasma metabolome in children from two longitudinal birth cohort studies. In Project Viva, current asthma was associated with alterations in metabolites from the nicotinamide pathway, pyrimidine metabolism, fibrinogen-associated peptides, bile metabolites and p-cresol sulphate, a microbial metabolite derived from the gut microbiome. Cortisone, a metabolite inversely associated with ICS use, 31 was decreased in current asthmatics. The association between asthma case status and two of the top metabolites (the bacterial metabolite p-cresol sulphate from the gut microbiome, and a nicotinoamide pathway metabolite) were replicated in a second cohort, the VDAART clinical trial.
Our study shows a new potential link between higher levels of plasma p-cresol sulphate and decreased odds of asthma. This association was replicated in an independent cohort. p-cresol sulphate is a microbial metabolite that may reflect gut microbiome composition. Odds ratios are for a 1 unit increase in metabolite level; all odds ratios are adjusted for maternal age, maternal education, smoking in pregnancy, child's BMI z-score, race/ethnicity, age and gender; Odds ratios with P < .05 in bold.
and asthma status is intriguing, further research is required to uncover the connection between the gut microbiome, the circulating metabolome, and their combined relationship to asthma.
We observed higher levels of the nicotinamide pathway metabolite N1-Methyl-2-pyridone-5-carboxamide in asthmatic subjects vs. controls in Project Viva, and our findings in VDAART were showed a similar relationship. The nicotinate and nicotinamide metabolic pathway has been linked to asthma phenotypes in both in vitro and population-based studies. One in vitro study of human airway smooth muscle demonstrated that cells from asthmatic donors had increased expression of NADPH (Nicotinamide Adenine Diphosphate) Oxidase, which promoted oxidative stress and smooth muscle cell contractility. 40 Other in vitro findings show increased NADPH oxidase expression in neutrophilic asthma, with a concomitant decrease in ciliary function of the bronchial epithelium. 41 These in vitro models provide a biological basis for our observed association between plasma nicotinamide metabolites and current asthma. While one other previous epidemiological study reported alterations in nicotinamide pathway metabolites (nicotinamide was increased in asthmatic subjects vs. controls), the sample size was small (30 subjects in total) and there were no attempts at replication. 42 Metabolomic profiles of asthmatics in our study also showed increased levels of two similar peptides likely derived from fibrinopeptide A (DSGEGDFXAEGGGVR and ADSGEGDFXAEGGGVR).
Fibrinopeptide A is a short amino acid sequence located within the alpha chain of soluble fibrinogen. Fibrinogen may play a role in asthma pathogenesis by enhancing inflammatory response. Huang and colleagues reported a correlation between increased plasma fibrinogen and reduced lung function. These investigators also found that obese subjects, including those with asthma, tend to have higher circulating fibrinogen levels. 43 Fibrinogen cleavage products act as TLR4 ligands, enhancing innate immune response. 44 For instance, fibrinogen cleavage products can bind Toll like receptor 4 (TLR4), priming innate immune and airway epithelial cell response to IL-13, with downstream triggering of airway inflammation. 45 Two of the metabolites with altered levels in current asthmatics, taurocholate and biliverdin, are bile constituents. Taurocholate, a conjugate of taurine and cholic acid, is an emulsifier of fats. Comhair and investigators previously reported increased plasma taurocholate in asthmatics, and we replicate that finding here in a much larger cohort. 42 Yu and colleagues also report altered levels of taurocholate in a mouse model of OVA-induced asthma 46 ; however, in this experimental study mice with the asthma phenotype had lower, as opposed to higher, levels of circulating taurocholate. Other experimental data suggest that activity of hemoxygenase-1, the enzyme that produces biliverdin from heme, may reduce mucous secretion in the airways. In an in vitro study of normal human bronchial epithelial cells, over-expression of heme oxygenase-I was associated with reduced IL-13 induced goblet cell hyperplasia and decreased MUCA5
secretion. 47 The lower levels of circulating biliverdin in asthma cases may reflect reduced activity of heme oxygenase I, which could potentially contribute to increased mucous production in the airways (a common feature of asthma).
Consistent with the findings of Reinke et al, 31 we also observed decreased plasma cortisone levels in subjects with current asthma. This finding is consistent with well-known effects of ICS (inhaled corticosteroid) use, which cause suppression of the hypothalamic-pituitary axis, leading to lower production of endogenous steroids like cortisone. 48 The decreased plasma cortisone levels in asthmatics vs. controls is most It is interesting to note that our PLS-DA analysis did not identify any global metabolite profile differences by asthma status, whereas analysis of individual metabolites did yield a number of biologically plausible associations. One interpretation of this finding is that asthma case Our study has several strengths. First, it is one of the largest plasma metabolomic studies comparing asthma cases to control subjects to date. Second, we limited potential sources of bias by controlling for confounders, including race, BMI and maternal educational level. Third, we were able to replicate two of our top metabolites in an independent cohort. Despite the strengths of our study, a few caveats deserve mention. First, utilizing maternal report of doctor diagnosis of asthma, rather than direct physician report of asthma diagnosis may have been potential source of bias in health outcome assessment. Second, while our study is large compared to other metabolomics studies, our sample size may have been too small to identify associations that were statistically significant after accounting for multiple comparisons. An additional limitation was that the phenotypes available for our discovery and replication cohorts were different. For Project Viva, current asthma status was assessed in mid-childhood, whereas VDAART subjects were assessed at age 3, when a definitive asthma diagnosis is often difficult. Also, the racial/ethnic and socioeconomic status distributions (while accounted for in our analyses) and different geographic locations for the primary and replication populations, may have given rise to very different exposure profiles (including diet) that could not be adjusted for in our analyses. Plasma samples in Project Viva were fasting, whereas in the replication population plasma samples were non-fasting. (The use of non-fasting samples in VDAART may have had a particular influence on our ability to detect an association between current asthma status and the dietary metabolite tryptophan betaine, if recent food intake increased the variability of this metabolite.) The study designs for Project Viva and VDAART were also different; Project Viva is an observational epidemiology study based on an unselected population, while VDAART is a clinical trial of prenatal vitamin D supplementation and asthma outcomes in children with a parental history of allergies or asthma. These discrepancies in the two cohorts may have decreased our potential for replication; however, our ability to replicate two metabolites in spite of these differences suggests that our replicated associations are robust. Metabolite identification in the two populations was not identical, which meant that we did not have the opportunity to test for replication of the phospholipid 1-docosapentaenoylglycerophosphocholine (22:5) and fibrinogen peptide findings, as these were not among the named metabolites in our replication study. It should also be noted that while many of the metabolites associated with asthma in our primary cohort are biologically plausible and supported by experimental data in the literature, none were statistically significant after adjustment for multiple comparisons.
In summary, our findings suggest that current asthma is associated with perturbations in pathways including metabolism of nicotinamide and pyrimidines, production of bile salts, heme catabolism and metabolites generated via the gut microbiome. Asthmatics in our cohort tended to have lower levels of endogenous cortisone, which is likely an effect of inhaled corticosteroid use. Identifying a metabolomic profile characteristic of children with asthma has the potential to uncover novel candidate pathways in asthma pathophysiology. In the long-term, asthma metabolomics research may identify biomarkers that improve the efficacy of therapeutic regimens for children with asthma, in turn decreasing the severity of asthma suffering and healthcare costs in the United States and globally.
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